{Reference Type}: Journal Article
{Title}: Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus.
{Author}: Ardizzone S;Armuzzi A;Caprioli F;Castiglione F;Danese S;Daperno M;Fantini MC;Fries W;Principi MB;Savarino E;Gionchetti P;
{Journal}: Dig Liver Dis
{Volume}: 56
{Issue}: 1
{Year}: 2024 Jan 21
{Factor}: 5.165
{DOI}: 10.1016/j.dld.2023.09.003
{Abstract}: <B>BACKGROUND: </B>Crohn's disease and ulcerative colitis are inflammatory bowel diseases (IBDs) with a rapidly growing worldwide incidence. The last decades presented rapid progress in pharmacological treatment leading in many cases to clinical and endoscopic remission, including biological treatment with anti-TNF agents.<BR><B>OBJECTIVE: </B>The exact timing of introduction, optimization and maintenance of anti-TNF therapy in IBDs is not thoroughly covered in current guidelines.<BR><B>METHODS: </B>We used the Delphi panel methodology to gather the IBD experts' views and achieve consensus for clinical recommendations on introducing and maintaining anti-TNF therapy for patients with IBDs.<BR><B>RESULTS: </B>Twelve recommendations achieved a high level of consensus in two assessment rounds by 52 (1st round) and 47 (2nd round) IBD experts.<BR><B>CONCLUSIONS: </B>In many clinical situations, the early use of anti-TNF therapy is recommended. Nowadays, the cost-efficacy profile of anti-TNF biosimilars makes them the first-line drug in a substantial proportion of patients, thus providing the opportunity to increase access to biological therapy.